Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma? - Beyond the Abstract
Written by Steven C. Campbell, MD, PhD, Professor of Surgery, Section of Urologic Oncology, Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic
June 17, 2021
The arguments in favor of partial nephrectomy (PN) over radical nephrectomy (RN) for patients with localized renal cell carcinoma (RCC) have been diverse and compelling,
1 leading many to advocate for PN whenever feasible, even for potentially aggressive tumors.
2 However, some patients with tumors with increased oncologic potential and/or high complexity may not be well-served by PN,
Read More
The Ongoing Evolution of a Field: Advances In First Line Therapy For Metastatic Clear Cell Renal Cell Carcinoma
Written by Zachary Klaassen, MD, MSc
March 31, 2021
Cancers of the kidney and renal pelvis (when considered in aggregate despite different histology) represent the 6
th most common newly diagnosed tumors in men and 8
th most common in women in the United States in 2020
1, representing an estimated 73,750 new diagnoses and 14,830 deaths.
Read More
The Risks of Delaying Kidney Cancer Treatment During COVID-19
Written by Zachary Klaassen, MD, MSc
April 21, 2020
The rapid spread of COVID-19 has had dramatic effects throughout the world on healthcare systems with impacts far beyond the patients actually infected with the disease. Patients with severe kidney cancer must rely on data and recommendations as to who can safely defer treatment until after the pandemic is over versus those that should be treated without delay.
Read More
First Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
Written by Zachary Klaassen, MD, MSc
March 17, 2020
Cancers of the kidney and renal pelvis comprise the sixth most common newly diagnosed tumors in men, the tenth most common in women in the United States, and account for an estimated 65,340 people new diagnoses and 14,970 cancer-related deaths in 2018 in the United States. Despite ongoing stage migration as a result of widespread use of axial abdominal imaging for non-specific abdominal complaints,
Read More
The Current Status of Stereotactic Body Radiation Therapy in Kidney Cancer
Written by Zachary Klaassen, MD MSc
November 20, 2019
Renal cancers are common, accounting for an estimated 65,340 new diagnoses and 14,970 attributable death in 2018 in the United States.1 The “Epidemiology and Etiology of Kidney Cancer” is discussed at length in the linked article in the UroToday Center of Excellence series.
Read More
Adjuvant Systemic Therapy for High Risk Kidney Cancer
Written by Zachary Klaassen, MD, MSc
December 6, 2019
With the widespread dissemination of abdominal imaging, there has been a stage migration in kidney cancer. However, this appears to have plateaued since 20071. There remains a significant proportion (~16%) of patients newly diagnosed with renal cell carcinoma who presented with advanced-stage disease and a further subset of those with localized disease are at high risk of recurrence.
Read More
The Current Status of Cytoreductive Nephrectomy
Written by Christopher J.D. Wallis, MD, PhD and Zachary Klaassen, MD, MSc
April 16, 2019
Kidney cancer is the 6th most common malignancy among men and 10th most among women.
1 Renal cell carcinoma (RCC) accounts for the vast majority of these tumors.
Read More
Malignant Renal Tumors
Renal cancers are common, accounting for an estimated 65,340 new diagnoses and 14,970 attributable deaths in 2018 in the United States.
1 In the article, "Epidemiology and Etiology of Kidney Cancer" both topics are discussed at great length.
Read More
First Line Therapy of Metastatic Clear Cell RCC
Written by Jason Zhu, MD
January 29, 2019
Kidney cancer represents 5% of all new cancer diagnoses in the United States, with approximately 64,000 new cases and 14,970 deaths in 2018.
1,2 The most common type of kidney cancer is renal cell carcinoma (RCC) and the most common histologic subtype of RCC is clear cell RCC, accounting for over 80% of cases.
3 Read More
Systemic Therapy for Advanced Renal Cell Carcinoma
As highlighted in prior articles on the Etiology and Epidemiology of Kidney Cancer, cancers of the kidney and renal pelvis comprise the 6th most common newly diagnosed tumors in men and 10th most common in women
1 and account for an estimated 65,340 people new diagnoses and 14,970 cancer-related deaths in 2018 in the United States.
Read More
Treatment of Metastatic Non-Clear Cell RCC
Written by Jason Zhu, MD
November 29, 2018
Kidney cancer is the 12th most common cancer in the world, with over 300,000 new cases annually, of which 65,340 new cases will be diagnosed in the United States in 2018.
1 The incidence of renal cell carcinoma (RCC) varies substantially based on the country – rates of RCC are higher in Europe and North America and much lower in Asia and South America.
2 Read More
Epidemiology and Etiology of Kidney Cancer
Kidney cancer is a broad, encompassing term that borders on colloquial. While most physicians are referring to renal cell carcinoma when they say “kidney cancer”, a number of other benign and malignant lesions may similarly manifest as a renal mass. Considering only the malignant causes, kidney cancers may include renal cell carcinoma,
Read More
Epidemiology and Etiology of Kidney Cancer
Kidney cancer is a broad, encompassing term that borders on colloquial. While most physicians are referring to renal cell carcinoma when they say “kidney cancer”, a number of other benign and malignant lesions may similarly manifest as a renal mass.
Read More
Nonsurgical Focal Therapy for Renal Tumors
As has been highlighted in the accompanying article on the Epidemiology and Etiology of Kidney Cancer, cancers of the kidney and renal pelvis comprise the 6th most common newly diagnosed tumors in men and 10th most common in women.
Read More
